IL-6, LIF, and TNF-α regulation of GM-CSF inhibition of osteoclastogenesis in vitro

Experimental Cell Research

Volumn 294, Issue 1, 2004, Pages 149-158

  Gorny, Genevieve ^a   Shaw, Aubie ^a   Oursler, Merry Jo ^b  

^a UNIVERSITY OF MINNESOTA DULUTH   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

GM CSF; IGF I; IGF II; IL 6; LIF; Osteoclastogenesis; TNF

Indexed keywords

COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOMATOMEDIN B; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; STROMA CELL;

EID: 1242339610     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.11.009     Document Type: Article

References (47)

1. Walker D.G. Osteopetrosis cured by temporary parabiosis. Science. 180:1973;875.
2. Suda T., Takahashi N., Martin T.J. Modulation of osteoclast differentiation. Endocr. Rev. 13:1992;66-80.
3. Suda T., Kobayashi K., Jimi E., Udagawa N., Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found. Symp. 232:2001;235-247. (discussion 247-50).
4. Reddy S., Roodman G.D. Control of osteoclast differentiation. Crit. Rev. Eukaryot. Gene Expr. 8:1998;1-17.
5. Martin T., Romas E., Gillespie M. Interleukins in the control of osteoclast differentiation. Crit. Rev. Eukaryot. Gene Expr. 8:1998;107-123.
6. Chihara K., Sugimoto T. The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts. Horm. Res. 48:1997;45-49.
7. Kaji H., Sugimoto T., Kanatani M., Nishiyama K., Nasu M., Chihara K. Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone. J. Cell. Physiol. 172:1997;55-62.
8. Fiorelli G., Formigli L., Zecchi Orldini S., Gori F., Falchetti A., Morelli A., Tanini A., Benvenuti S., Brandi M.L. Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Bone. 18:1996;269-276.
9. Hill P., Reynolds J., Meikle M. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology. 136:1995;124-131.
10. Baylink D.J., Finkelman R.D., Mohan S. Growth factors to stimulate bone formation. J. Bone Miner. Res. 8(Suppl. 2):1993;S565-S572.
11. Mochizuki H., Hakeda Y., Wakatsuki N., Usui N., Akashi S., Sato T., Tanaka K., Kumegawa M. Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology. 131:1992;1075.
12. Slootweg M., Most W., van Beek E., Schot L., Papapoulos S., Lowik C. Osteoclast formation together with interleukin-6 production in mouse long bones is increased by insulin-like growth factor-I. J. Endocrinol. 132:1992;433-438.
13. Miyamoto T., Ohneda O., Arai F., Iwamoto K., Okada S., Takagi K., Anderson D.M., Suda T. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood. 98:2001;2544-2554.
14. Hattersley G., Chambers T. Effects of interleukin 3 and of granulocyte-macrophage and macrophage colony stimulating factors on osteoclast differentiation from mouse hemopoietic tissue. J. Cell. Physiol. 142:1990;201-209.
15. Fujikawa Y., Sabokbar A., Neale S.D., Itonaga I., Torisu T., Athanasou N.A. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone. 28:2001;261-267.
16. Yamazaki H., Kunisada T., Yamane T., Hayashi S.I. Presence of osteoclast precursors in colonies cloned in the presence of hematopoietic colony-stimulating factors. Exp. Hematol. 29:2001;68-76.
17. Liggett W.J., Shevde N., Anklesaria P., Sohoni S., Greenberger J., Glowacki J. Effects of macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor on osteoclastic differentiation of hematopoietic progenitor cells. Stem Cells. 11:1993;398-411.
18. Wiebe S.H., Hafezi M., Sandhu H.S., Sims S.M., Dixon S.J. Osteoclast activation in inflammatory periodontal diseases. Oral Dis. 2:1996;167-180.
19. Neale S.D., Sabokbar A., Howie D.W., Murray D.W., Athanasou N.A. Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption. J. Orthop. Res. 17:1999;686-694.
20. Xu J.W., Konttinen Y.T., Lassus J., Natah S., Ceponis A., Solovieva S., Aspenberg P., Santavirta S. Tumor necrosis factor-alpha (TNF-alpha) in loosening of total hip replacement (THR). Clin. Exp. Rheumatol. 14:1996;643-648.
21. Pederson L., Winding B., Foged N., Spelsberg T., Oursler M. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res. 59:1999;5849-5855.
22. Clohisy D.R., Palkert D., Ramnaraine M.L., Pekurovsky I., Oursler M.J. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. J. Orthop. Res. 14:1996;396-402.
23. Suda T., Nakamura I., Jimi E., Takahashi N. Regulation of osteoclast function. J. Bone Miner. Res. 12:1997;869-879.
24. Roodman G.D. Advances in bone biology: the osteoclast. Endocr. Rev. 17:1996;308-332.
25. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 142:2001;5050-5055.
26. Atkins G.J., Haynes D.R., Geary S.M., Loric M., Crotti T.N., Findlay D.M. Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone. 26:2000;653-661.
27. Atkins G.J., Haynes D.R., Graves S.E., Evdokiou A., Hay S., Bouralexis S., Findlay D.M. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner. Res. 15:2000;640-649.
28. Mancino A.T., Klimberg V.S., Yamamoto M., Manolagas S.C., Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res. 100:2001;18-24.
29. Massey H.M., Scopes J., Horton M.A., Flanagan A.M. Transforming growth factor-beta1 (TGF-beta) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment. Bone. 28:2001;577-582.
30. Quinn J.M., Itoh K., Udagawa N., Hausler K., Yasuda H., Shima N., Mizuno A., Higashio K., Takahashi N., Suda T., Martin T.J., Gillespie M.T. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16:2001;1787-1794.
31. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., Nakagawa N., Yasuda H., Goto M., Tsuda E., Higashio K., Gillespie M.T., Martin T.J., Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 25:1999;517-523.
32. Wei S., Wang M.W., Teitelbaum S.L., Ross F.P. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J. Biol. Chem. 277:2002;6622-6630.
33. Ragab A.A., Nalepka J.L., Bi Y., Greenfield E.M. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am. J. Physiol., Cell Physiol. 283:2002;C679-C687.
34. Gingery A., Bradley E., Shaw A., Oursler M.J. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J. Cell. Biochem. 89:2003;165-179.
35. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
36. Roodman G.D. Cell biology of the osteoclast. Exp. Hematol. 27:1999;1229-1241.
37. Suda T., Udagawa N., Nakamura I., Miyaura C., Takahashi N. Modulation of osteoclast differentiation by local factors. Bone. 17:1995;87S-91S.
38. Richards C.D., Langdon C., Deschamps P., Pennica D., Shaughnessy S.G. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine. 12:2000;613-621.
39. Palmqvist P., Persson E., Conaway H.H., Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 169:2002;3353-3362.
40. Scheven B.A., Milne J.S., Robins S.P. A novel culture system to generate osteoclasts and bone resorption using porcine bone marrow cells: role of M-CSF. Biochem. Biophys. Res. Commun. 231:1997;231-235.
41. Rubin J., Ackert-Bicknell C.L., Zhu L., Fan X., Murphy T.C., Nanes M.S., Marcus R., Holloway L., Beamer W.G., Rosen C.J. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J. Clin. Endocrinol. Metab. 87:2002;4273-4279.
42. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275:2000;768-775.
43. Campbell I.K., Novak U., Cebon J., Layton J.E., Hamilton J.A. Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1. J. Immunol. 147:1991;1238-1246.
44. Lowik C.W., van der Pluijm G., Bloys H., Hoekman K., Bijvoet O.L., Aarden L.A., Papapoulos S.E. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162:1989;1546-1552.
45. Kurzrock R., Estrov Z., Wetzler M., Gutterman J.U., Talpaz M. LIF: not just a leukemia inhibitory factor. Endocr. Rev. 12:1991;208-217.
46. van der Pluijm G., Most W., van der Wee-Pals L., de Groot H., Papapoulos S., Lowik C. Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology. 129:1991;1596-1604.
47. Servet-Delprat C., Arnaud S., Jurdic P., Nataf S., Grasset M.F., Soulas C., Domenget C., Destaing O., Rivollier A., Perret M., Dumontel C., Hanau D., Gilmore G.L., Belin M.F., Rabourdin-Combe C., Mouchiroud G. Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia. BMC Immunol. 3:2002;15.